The key finding
A comprehensive 2024 review in the Journal of Hematology & Oncology reveals that pancreatic cancer remains exceptionally difficult to treat despite expanding treatment options. While doctors now have consensus on surgical approaches focused on complete tumor removal (R0 resection), major debates persist around when to use chemotherapy before surgery and which drug combinations work best. For advanced disease, standard chemotherapy regimens like FOLFIRINOX and gemcitabine/nab-paclitaxel remain the backbone of treatment, but newer approaches including immunotherapy and targeted drugs are showing promise in small patient subsets. The sobering reality: even with multi-modality strategies combining surgery, chemotherapy, and experimental therapies, overall survival improvements have been modest.
What the study looked like
This was not a single experiment but rather a comprehensive clinical review synthesizing current evidence on pancreatic cancer treatments across all disease stages. The authors examined treatment outcomes for resectable (surgically removable), borderline resectable, and advanced or metastatic pancreatic cancer. They analyzed data from multiple clinical trials testing various chemotherapy combinations, including FOLFIRINOX (a four-drug regimen), gemcitabine paired with nab-paclitaxel or capecitabine, and the newer NALIRIFOX protocol. The review also assessed emerging immunotherapy and targeted therapy trials, focusing on specific patient populations like those with microsatellite instability-high (MSI-H) tumors or specific genetic mutations like KRAS or BRCA. The synthesis covered both established standard-of-care treatments and investigational approaches currently being tested.
Why researchers think this happened
The authors emphasize that pancreatic cancer behaves as a systemic disease from early stages, meaning cancer cells likely spread beyond the pancreas before detection in most patients. This biological aggressiveness explains why even successful surgery often fails to cure the disease. The tumor’s microenvironment—the surrounding tissue and immune cells—actively suppresses immune responses, which explains why immunotherapy works only in a tiny fraction of patients (those with MSI-H, deficient mismatch repair, or high tumor mutational burden). These represent less than 5% of pancreatic cancer cases. The review highlights that combination strategies attempting to “wake up” the immune system or make tumors more visible to immune cells may be necessary. Meanwhile, targeted therapies like PARP inhibitors work specifically in patients with BRCA mutations, while KRAS inhibitors target a common genetic driver mutation, but both are linked to improvements in progression-free survival rather than dramatic long-term survival gains.
How to read this carefully
This is a narrative review, not a randomized trial, meaning it synthesizes existing evidence rather than generating new data. The authors discuss ongoing debates in the field, indicating that even experts disagree on optimal treatment sequencing—particularly whether resectable patients should receive chemotherapy before or only after surgery. The “modest” survival improvements mentioned are relative to a disease with historically dismal outcomes; small gains matter but shouldn’t be overstated. Additionally, the promising targeted and immunotherapies mentioned work only in specific genetic or molecular subsets of patients, often requiring specialized testing to identify eligible individuals. Many of these newer approaches show benefits in progression-free survival (delaying cancer growth) rather than overall survival (living longer), an important distinction that doesn’t always translate to extended life.
What this means for everyday life
For anyone facing a pancreatic cancer diagnosis or supporting someone who is, this review underscores the importance of seeking care at specialized centers where multidisciplinary teams can navigate complex treatment decisions. The existence of multiple chemotherapy regimens and the need for genetic testing (for MSI status, BRCA mutations, KRAS status) suggests that personalized treatment planning matters. The ongoing debates about treatment timing and combinations also highlight why second opinions can be valuable—there isn’t always one “right” answer. For the broader public, this review serves as a reminder of why pancreatic cancer research funding remains critical; unlike some cancers where survival has improved dramatically, this disease continues to resist our best efforts, making every research advance particularly hard-won and worthy of support.